Q-omics provides the consensus-scored KRT26 profile across patient tissues and cancer cell-line models. KRT26 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KRT26 is differentially expressed in 2, with the highest sampling consensus in KIRP. Additionally, KRT26 RNA expression shows 5,521 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, KIRP, and STAD as cancer lineages where KRT26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT26 survival associations across molecular data types. KRT26 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT26 RNA expression–survival associations across cancer types. High KRT26 expression shows unfavorable associations in KIRC, KIRP, PAAD, KICH, BLCA and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KRT26 RNA expression.
This table summarizes KRT26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for KRT26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT26 shows higher tumor expression in KIRP and LUSC. The KIRP box plot shows higher KRT26 RNA expression in tumor versus normal tissue (log2 FC = +0.040, t-test p = .046).
This table shows molecular features associated with KRT26 in patient tissues and cancer cell lines. In patient samples, KRT26 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and SOFT_TISSUE.
